Compare RDNT & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | RLAY |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 1996 | 2020 |
| Metric | RDNT | RLAY |
|---|---|---|
| Price | $72.39 | $19.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $82.80 | $19.50 |
| AVG Volume (30 Days) | 645.3K | ★ 2.2M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,616,630,000.00 | $15,355,000.00 |
| Revenue This Year | $22.78 | N/A |
| Revenue Next Year | $10.70 | $324.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.05 | ★ 53.44 |
| 52 Week Low | $50.82 | $3.15 |
| 52 Week High | $85.84 | $20.79 |
| Indicator | RDNT | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 62.91 | 59.15 |
| Support Level | $64.71 | $18.02 |
| Resistance Level | $71.79 | $20.59 |
| Average True Range (ATR) | 2.69 | 0.96 |
| MACD | 0.50 | -0.06 |
| Stochastic Oscillator | 86.53 | 76.12 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.